Clinical response to chemotherapy and hormone therapy as first treatment after therapeutic ovariectomy in advanced breast cancer patients.
The results of chemotherapy and hormone therapy, administered after relapse of the disease, were evaluated in 106 patients with homogeneous clinical characteristics who were subjected to bilateral ovariectomy for advanced breast cancer, whether the response to castration was favorable or not. In spite of an unfavorable response to the ovariectomy, 40.0% of the patients responded to hormone therapy, whereas 32.5% of the cases did not benefit from the successive hormone therapy, although they had responded to ovariectomy. The contrast, 65%, after favorably responding to ovariectomy, showed regression of the neoplasm after chemotherapy for the relapse. This apparent discordance of the results could be due to the fact that response to castration is not the only valid parameter to identify hormone dependence of a breast cancer and/or that the breast cancer is composed, in various proportions, of hormone-sensitive and chemo-sensitive cells. The predominance of one of these 2 components could determine the response of the neoplasm to therapy. The authors conclude that a more extensive and accurate hormone typing of the patient could give more precise indications for the appropriate therapy.
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000628:therapy*; D002369:Castration; D003520:Cyclophosphamide / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006728:Hormones / Q000627:therapeutic use*; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use; D008777:Methyltestosterone / Q000627:therapeutic use; D008875:Middle Aged; D009376:Neoplasms, Hormone-Dependent / Q000628:therapy*; D011372:Progestins / Q000627:therapeutic use; D013629:Tamoxifen / Q000627:therapeutic use; D013739:Testosterone / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D006728:Hormones; D011372:Progestins; D013629:Tamoxifen; D013739:Testosterone; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D005472:Fluorouracil; D008777:Methyltestosterone; D008727:Methotrexate